Brainstorm Cell Therapeutics (NASDAQ:BCLI) Upgraded to “Hold” at StockNews.com

StockNews.com upgraded shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) from a sell rating to a hold rating in a research note issued to investors on Wednesday.

Brainstorm Cell Therapeutics Trading Up 2.0 %

NASDAQ BCLI opened at $2.03 on Wednesday. The stock has a fifty day simple moving average of $1.93 and a 200-day simple moving average of $2.96. The stock has a market cap of $11.57 million, a PE ratio of -0.42 and a beta of 0.29. Brainstorm Cell Therapeutics has a twelve month low of $1.05 and a twelve month high of $11.89.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc, a biotechnology company, engages in the development and commercialization of autologous cellular therapies for the treatment of neurodegenerative diseases. The company, through its NurOwn proprietary cell therapy platform, leverages cell culture methods to induce autologous bone marrow-derived mesenchymal stem cells to secrete high levels of neurotrophic factors, modulate neuroinflammatory and neurodegenerative disease processes, promote neuronal survival, and enhance neurological function.